Načítá se...
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors
Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP‐4; also termed CD26) inhibitors, also called gliptins. Gliptins inhibit the degradati...
Uloženo v:
| Vydáno v: | Br J Clin Pharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6046494/ https://ncbi.nlm.nih.gov/pubmed/29667232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13611 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|